Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 4203 Official Publication of Indian Association of Medical Microbiologists 
 ~   Next article
 ~   Previous article
 ~   Table of Contents

 ~   Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~   Citation Manager
 ~   Access Statistics
 ~   Reader Comments
 ~   Email Alert *
 ~   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2063    
    Printed55    
    Emailed1    
    PDF Downloaded124    
    Comments [Add]    

Recommend this journal

 

 BRIEF COMMUNICATION
Year : 2014  |  Volume : 32  |  Issue : 1  |  Page : 60-63

Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent


1 Departments of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India
2 Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India

Correspondence Address:
P Abraham
Departments of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu
India
Login to access the Email id

Source of Support: The study was supported by Indian Council for Medical Research (ICMR) grant (No. 5/8/7/7/2008-ECD-I),, Conflict of Interest: None


DOI: 10.4103/0255-0857.124312

Rights and Permissions

Adefovir is one of the therapeutic options for the treatment of chronic hepatitis B. A total of 30 adefovir-experienced subjects with the median treatment duration of 12 (interquartile range (IQR) 6-18) months were studied. Virological response was measured by hepatitis B virus deoxyribonucleic acid (HBV DNA) levels. HBV reverse transcriptase (rt) domains were sequenced for the identification of resistance mutations. Among the 30 subjects, two (7%) showed virological response and 19 (63%) were non-responders. The virological response for the remaining nine (30%) subjects was not determined. On sequence analysis, two subjects were identified with rtI169L and rtA181V mutation after 9 months and 18 months of adefovir treatment, respectively. Though the frequencies of adefovir resistance mutations are low, a large majority of subjects showed non-response. Therefore, adefovir in the management of HBV should be used judiciously.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04